Neogenomics, Inc.
Could not find a ticker for this position, may be a filing error
A laboratory that focuses exclusively on cancer testing, helping oncologists and pathologists diagnose tumors and choose treatments through genetic and molecular analysis. Founded in 2001 in Fort Myers, Florida, by a pathologist and a healthcare executive, it has grown into one of the largest oncology-focused reference labs in the United States. The name blends "neo" — Greek for "new" — with "genomics," a nod to the modern genetic techniques at its core.
1.25% Convertible Senior Notes due May 1, 2025
Granted 707.7K
Granted 295.3K · Bought 17.0K
Granted 61.1K
Granted 233.0K · Bought 40.0K
Granted 164.1K · Bought 36.8K
Granted 205.3K · Sold 28.2K
Granted 257.7K · Bought 5.7K · Sold 22.1K
Granted 147.9K · Sold 100.0K
Granted 87.9K
Granted 39.1K
Granted 148.5K
Granted 123.7K
Granted 123.3K · Sold 38.4K
Granted 67.9K · Bought 7.0K · Sold 16.7K
Granted 24.7K
Granted 62.2K · Bought 4.0K
Granted 62.2K · Bought 5.0K
Granted 57.0K · Bought 10.0K
Granted 15.6K
Granted 46.7K · Bought 4.5K
Granted 37.7K · Sold 1.8K
Granted 21.4K
Granted 43.2K
Granted 30.6K
Granted 3.3K
Granted 27.0K
Granted 30.2K
Granted 30.1K
Granted 17.1K
Granted 23.6K
Granted 23.0K
Granted 15.6K
Granted 17.2K
Granted 5.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Smith Christopher MChief Executive Officer · 7 transactions | — | 641.6Kas of Feb 2025 | 707.7K | — | — |
| Mallon MarkChief Executive Officer, Director · 3 transactions | +560.3% | 368.1Kas of Mar 2022 | 295.3K | 17.0K | — |
| Cardoza GeorgePresident & COO, Lab Ops · 3 transactions | +29.3% | 264.2Kas of Mar 2022 | 61.1K | — | — |
| Sherman Jeffrey ScottChief Financial Officer · 17 transactions | — | 220.0K | 233.0K | 40.0K | — |
| Zook Anthony P.Chief Executive Officer, Director · 7 transactions | — | 209.0K | 164.1K | 36.8K | — |
| Bonello WilliamChief Financial Officer · 11 transactions | +1621.3% | 191.5Kas of Apr 2022 | 205.3K | — | 28.2K |
| Stone WarrenPres & Chief Operating Officer · 27 transactions | — | 167.8K | 257.7K | 5.7K | 22.1K |
| Brown Douglas MatthewChief Strategy Officer · 7 transactions | +48.3% | 158.7Kas of Apr 2022 | 147.9K | — | 100.0K |
| Gilbert Halley EChief Legal Officer · 3 transactions | +132.7% | 147.4Kas of Mar 2022 | 87.9K | — | — |
| Hannah Alison L.Director · 3 transactions | +42.6% | 131.0Kas of Jun 2025 | 39.1K | — | — |
| Sikri VishalPresident Advanced Diagnostics · 3 transactions | — | 128.9Kas of Feb 2024 | 148.5K | — | — |
| Harris MelodyChf Ops Off, Pres, Informatics · 7 transactions | — | 109.8Kas of Feb 2025 | 123.7K | — | — |
| Olivo Alicia CEVP, GC & Business Development · 33 transactions | — | 93.6K | 123.3K | — | 38.4K |
| Tetrault LYNN A.Director · 11 transactions | — | 93.1K | 67.9K | 7.0K | 16.7K |
| Kulkarni ShashikantChief Scientific Officer · 2 transactions | — | 82.7Kas of Apr 2023 | 24.7K | — | — |
| Kanovsky Stephen MDirector · 5 transactions | +720% | 75.4K | 62.2K | 4.0K | — |
| Kelly Michael AaronDirector · 5 transactions | — | 72.1K | 62.2K | 5.0K | — |
| Perez David BrianDirector · 5 transactions | — | 67.0K | 57.0K | 10.0K | — |
| Crowther Bruce KDirector · 1 transaction | +9.3% | 65.1Kas of Aug 2023 | 15.6K | — | — |
| Gunn NeilDirector · 4 transactions | — | 51.2K | 46.7K | 4.5K | — |
| McKenzie Kathryn BChief Sustainability/Risk Ofcr · 4 transactions | +264.7% | 49.4Kas of Jan 2022 | 37.7K | — | 1.8K |
| Balliet JenniferVP and Chief Culture Officer · 1 transaction | +78.6% | 48.6Kas of Dec 2021 | 21.4K | — | — |
| Sholehvar DavidPresident, Clinical Services · 2 transactions | — | 43.2Kas of Aug 2022 | 43.2K | — | — |
| Morris ClivePresident of Inivata · 1 transaction | +285.5% | 41.3Kas of Dec 2021 | 30.6K | — | — |
| Johnson Kevin CDirector · 1 transaction | +9.8% | 37.4Kas of Dec 2021 | 3.3K | — | — |
| Wallar Gina MPresident, Pharma Services · 3 transactions | +712.3% | 33.4Kas of Mar 2022 | 27.0K | — | — |
| Williams FeliciaDirector · 2 transactions | — | 30.2K | 30.2K | — | — |
| Dieter Cynthia JChief Accounting Officer · 8 transactions | +1562.8% | 29.8Kas of Mar 2023 | 30.1K | — | — |
| Aunan Greg DChief Accounting Officer · 9 transactions | — | 25.2K | 17.1K | — | — |
| Floegel ElizabethDirector · 2 transactions | — | 23.6Kas of Jun 2025 | 23.6K | — | — |
| Green Marjorie CDirector · 1 transaction | — | 23.0K | 23.0K | — | — |
| Stahler Rachel ADirector · 1 transaction | +269.2% | 21.3Kas of Jun 2022 | 15.6K | — | — |
| Daly DavidDirector · 2 transactions | — | 17.2Kas of Jun 2022 | 17.2K | — | — |
| Kenny John P.Director · 1 transaction | — | 5.9K | 5.9K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -77.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.